# Phase 1 arthritis trials recruiting: 52 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials in phase 1 for arthritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 arthritis trials: 52 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/arthritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Rheumatoid Arthritis and Systemic Lupus Erythematosus | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923747) |
| November 2, 2026 | NCT07908641 | Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release... | Amgen | Phase 1 | Not yet recruiting | Psoriasis, Arthritis, Psoriatic, Oral Ulcer | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908641) |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| August 4, 2026 | NCT07744828 | A Study to Evaluate Pharmacokinetics of DRL\_AB in Healthy Male Participants | Dr. Reddy's Laboratories Limited, India | Phase 1 | Not yet recruiting | Healthy Volunteers | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744828) |
| July 28, 2026 | NCT07729995 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | Luminary Therapeutics | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc) | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729995) |
| July 20, 2026 | NCT07712939 | A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases | Candid Therapeutics | Phase 1 | Recruiting | Healthy Participants Study, Rheumatoid Arthritis, Sjogren's Syndrome | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712939) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| May 27, 2026 | NCT07607964 | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous... | AbbVie | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607964) |
| May 4, 2026 | NCT07564154 | A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) | Kali Therapeutics, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis (RA) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564154) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| March 17, 2026 | NCT07478679 | Radiation to Treat Joint Damage Caused by Cancer Immunotherapy | University of Chicago | Phase 1 | Not yet recruiting | Arthritis, Arthropathy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478679) |
| March 6, 2026 | NCT07455578 | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | Seismic Therapeutic AU Pty Ltd | Phase 1 | Recruiting | Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455578) |
| February 25, 2026 | NCT07433335 | A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis | SciRhom GmbH | Phase 1 | Recruiting | Rheumatoid Arthritis | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433335) |
| January 28, 2026 | NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) | GlaxoSmithKline | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371468) |
| January 23, 2026 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363590) |
| December 17, 2025 | NCT07290036 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | UCB Biopharma SRL | Phase 1 | Recruiting | Psoriatic Arthritis, Axial Spondyloarthritis | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290036) |
| December 11, 2025 | NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | Eli Lilly and Company | Phase 1 | Recruiting | Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276958) |
| December 2, 2025 | NCT07258849 | A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | Eli Lilly and Company | Phase 1 | Recruiting | Rheumatoid Arthritis (RA) | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258849) |
| November 24, 2025 | NCT07245992 | A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis | Philogen S.p.A. | Phase 1 | Recruiting | Rheumatoid Arthritis (RA) | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245992) |
| November 20, 2025 | NCT07237659 | Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA | Neutrolis | Phase 1 | Recruiting | SLE (Systemic Lupus), RA - Rheumatoid Arthritis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07237659) |
| November 18, 2025 | NCT07234773 | A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). | Kali Therapeutics, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis (RA) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234773) |
| November 17, 2025 | NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | Xencor, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230353) |
| October 6, 2025 | NCT07207954 | Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | Lifordi Immunotherapeutics, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07207954) |
| October 1, 2025 | NCT07201558 | Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants | AstraZeneca | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201558) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| R3 Stem Cell | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Kali Therapeutics, Inc. | 2 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [UCB Biopharma SRL](https://specstream.ai/data/clinical-trials/company/ucb-biopharma-srl) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Lifordi Immunotherapeutics, Inc. | 1 |
| Capstan Therapeutics | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |
| Baylx Inc. | 1 |
| University of Rochester | 1 |
| Rise Therapeutics LLC | 1 |
| Sonoma Biotherapeutics, Inc. | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| Cullinan Therapeutics Inc. | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| The Foundation for Orthopaedics and Regenerative Medicine | 1 |
| IRIS Research and Development, LLC | 1 |
| Adicet Therapeutics | 1 |
| National Cancer Institute (NCI) | 1 |
| Luminary Therapeutics | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| China | 13 |
| Australia | 12 |
| Germany | 8 |
| Georgia | 5 |
| Poland | 5 |
| France | 5 |
| Spain | 5 |
| Japan | 5 |
| Moldova | 4 |
| New Zealand | 4 |
| Italy | 4 |
| Canada | 3 |
| Belgium | 3 |
| Romania | 3 |
| Brazil | 3 |
| Ukraine | 2 |
| Israel | 2 |
| Netherlands | 2 |
| Czechia | 2 |
| United Kingdom | 2 |
| Taiwan | 2 |
| Greece | 1 |
| Switzerland | 1 |
| Bosnia and Herzegovina | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [Fitness equipment wholesalers in the United States](https://specstream.ai/data/businesses/fitness-equipment-wholesalers/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Hotel supply companies in the United States](https://specstream.ai/data/businesses/hotel-supply-companies/united-states)
- [Irish restaurants in the United States](https://specstream.ai/data/businesses/irish-restaurants/united-states)
